DALLAS--(BUSINESS WIRE)--
Genomics England and Lantern
Pharma, a clinical stage pharma company specializing in precision
oncology using artificial intelligence, announced today that Lantern
will join Genomics England’s Discovery
Forum industry partnership. The partnership aims to translate
groundbreaking research into innovative treatments, and ultimately
patient benefit, as rapidly as possible.
This press release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20180226006727/en/
Lantern Pharma is reinventing the cancer drug development process,
tailoring multiple promising precision drug programs to the right cancer
patients through use of their RADRTM platform (Response
Algorithm for Drug Rescue and Positioning). Right
patient stratification is still considered by many in pharma as the holy
grail. Lantern is disrupting this using seamless integration of relevant
existing data, generation of new clean data closely modeling real world
evidence and very focused artificial intelligence technology application
to further model this data and distill into meaningful information that
can identify & stratify right patients with high accuracy. Even a small
step ahead in the right direction will be a huge leap for the pharma
industry.
Lantern is currently leading the way in AI directed drug development,
recently having fast tracked shelved assets from in-license to
out-license within 18 months in a total deal worth up to $21M. Lantern
are currently progressing 3 clinical stage drugs in using this
technology. Lantern aims to develop 10+ precision oncology treatments
over the next 2 years by opening up access to its RADR platform to other
pharmaceutical companies. Lantern is building a wide, global tissue and
data access network to enable the success of its precision programs.
Partnering with Genomics England will further strengthen this objective.
Genomics England is a UK Department of Health and Social Care owned
company, set up to deliver the 100,000 Genomes Project. The Project is
the largest of its kind in the world, and aims to sequence 100,000
genomes from around 70,000 people with rare disease and cancer.
Combining this with their health data will enable more diagnoses and
improved personalised treatments for patients in the future. The
Genomics England Discovery Forum provides an engagement platform for
industry partners, academia, the NHS, and the wider genomics community.
More than 30 of the world’s leading genomics companies come together
within the Forum to work in a pre-competitive environment with access to
de-identified whole genome data from the 100,000 Genomes Project.
Lantern already have bases in both the US and India and have recently
established a UK operation to work more closely with the European pharma
industry.
Arun Asaithambi, Lantern Pharma CEO, said:
“We are delighted to have been invited to participate in the Discovery
Forum and look forward to working with Genomics England, other Forum
members and the wider UK life science ecosystem to advance developments
in precision oncology.”
Professor Joanne Hackett, Genomics England Chief Commercial Officer,
said:
“By partnering with industry from the outset, our aim is to maximise the
potential for patient benefit through whole genome sequencing. We’re
delighted that Lantern Pharma have joined the Discovery Forum – as their
expertise will ultimately help turn research findings into treatments,
diagnostics and benefits for patients as soon as possible.”
About Lantern Pharma Inc
Lantern Pharma is a late clinical stage precision oncology company that
is using proprietary tech platform called RADR to identify drug specific
complex genetic signatures (potential CDX) for potential responders
identification and stratification with a high prediction accuracy to
conduct focused precision clinical trials. RADR is integrating any
existing clinical data, with data generated from wet-lab approach
closely modeling real world evidence/clinical trials and artificial
intelligence to identify genetic signatures and right responders.
Lantern Pharma Inc has 3 drugs in the pipeline, Irofulven-1
out-licensed, Irofulven-2 (prostate and ovarian) entering clinical
development, Tavocept, a Ph3 NSCLC cancer drug. Lantern is continuously
looking to in-license or acquire or partner drugs programs and RADR
Tech. Lantern also is building a tissue and data access network to
enable the success of the precision programs.
Lantern's approach can improve success of the drug, lower developmental
costs and time many folds vs traditional drug developmental processes.
www.lanternpharma.com
About Genomics England
Genomics England is a company owned by the Department of Health and was
set up to deliver the 100,000 Genomes Project. This flagship project
will sequence 100,000 whole genomes from NHS patients and their families.
Genomics England has four main aims:
-
to bring benefit to patients
-
to create an ethical and transparent programme based on consent
-
to enable new scientific discovery and medical insights
-
to kickstart the development of a UK genomics industry
The project is focusing on patients with rare diseases, and their
families, as well as patients with common cancers.
www.genomicsengland.co.uk
View source version on businesswire.com: http://www.businesswire.com/news/home/20180226006727/en/
Lantern Pharma
Arun Asaithambi, PhD, 469-520-0320
arun@lanternpharma.com
Source: Lantern Pharma
Released February 26, 2018